The Collier Report of U.S. Government Contracting

Old School Reporting Using Modern Technology

Home
>
New Jersey
>
Summit
>
Celgene Corporation

Celgene Corporation

  • Celgene Corporation

  • View government funding actions
  • Summit, NJ 079013915
  • Phone: 732-564-3480
  • Estimated Number of Employees: 2,000
  • Estimated Annual Receipts: $950,000,000
  • Business Start Date: 1986
  • Contact Person: David Clark
  • Contact Phone: 908-219-0885
  • Contact Email: davclark@celgene.com
  • Business Structure:
  • Corporate Entity (Not Tax Exempt)
  • Business Type:
  • For Profit Organization
  • Manufacturer of Goods
  • Industries Served: Pharmaceutical Preparation Manufacturing
  • Product Areas: MISCELLANEOUS ITEMS

Sampling of Federal Government Funding Actions/Set Asides

In order by amount of set aside monies.

  • $9,844 - Wednesday the 13th of March 2013
    Veterans Affairs Department
    516-BAY PINES
    VIDAZA
  • $95 - Thursday the 19th of July 2012
    Veterans Affairs Department
    516-BAY PINES
    REVLIMID 10 MG
  • $8,311 - Wednesday the 4th of April 2012
    Veterans Affairs Department
    262-NETWORK CONTRACT OFFICE 22
    VIDAZA 100 MG VIAL
  • $7,352 - Friday the 20th of July 2012
    Veterans Affairs Department
    516-BAY PINES
    REVLIMID 15 MG
  • $7,352 - Friday the 13th of July 2012
    Veterans Affairs Department
    516-BAY PINES
    REVLIMID 15 MG
  • $7,352 - Friday the 2nd of August 2013
    Veterans Affairs Department
    516-BAY PINES
    EMERGENCY DRUG ORDER
  • $7,352 - Friday the 2nd of August 2013
    Veterans Affairs Department
    516-BAY PINES
    DRUG ORDER - REVLIMID TAB
  • $7,334 - Friday the 2nd of August 2013
    Veterans Affairs Department
    516-BAY PINES
    EMERGENCY DRUG ORDER
  • $7,334 - Friday the 20th of July 2012
    Veterans Affairs Department
    516-BAY PINES
    REVLIMID
  • $6,917 - Thursday the 19th of July 2012
    Veterans Affairs Department
    516-BAY PINES
    REVLIMID 5 MG

© Copyright 2019
The Collier Report published by 1918 Media LLC.
Information displayed in this dossier has been provided through available open source or public sources. No reliance should be made by readers or Collier Report subscribers. Funding actions are complicated and do not always represent dollar-for-dollar payments to vendors nor do they represent payments in certain instances. Requests for the modification of displayed information may be made to help.desk@1918.media.